metronidazole has been researched along with ethambutol in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Cedillo-Rivera, R; Chan-Bacab, MJ; Estrada-Soto, S; Guerrero-Alvarez, J; León-Rivera, I; Mirón-López, G; Molina-Salinas, GM; Moo-Puc, R; Nava-Zuazo, C; Navarrete-Vazquez, G; Said-Fernández, S | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chaturvedi, V; Dasgupta, A; Gupta, AD; Jaiswal, S; Kashyap, VK; Khan, SR; Krishnan, MY; Lal, J; Roy, KK; Saxena, AK; Sharma, A; Sharma, SK; Singh, S; Sinha, S; Srivastava, R | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Sinha, PK; Thakur, CP | 1 |
| Hodges, GR; Snavely, SR | 1 |
| Flenley, DC | 1 |
| Koromihis, G; Libman, M; MacLean, JD; Semret, M; Ward, BJ | 1 |
| Kibadi, K | 1 |
| Caminero Luna, JA; Cerezo Lajas, A; de Miguel Díez, J; Rodríguez Guzmán, MDC | 1 |
3 review(s) available for metronidazole and ethambutol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The neurotoxicity of antibacterial agents.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Central Nervous System Diseases; Cephalosporins; Chloramphenicol; Clindamycin; Colistin; Cranial Nerve Diseases; Dapsone; Erythromycin; Ethambutol; Humans; Lincomycin; Metronidazole; Nervous System Diseases; Neuromuscular Junction; Penicillins; Peripheral Nervous System Diseases; Polymyxin B; Sulfonamides; Tetracyclines; Vancomycin | 1984 |
New drugs in respiratory disorders: II.
Topics: Adult; Aged; Amantadine; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Cephalosporins; Cyclophosphamide; Drug Combinations; Erythromycin; Ethambutol; Humans; Metronidazole; Pyrazinamide; Respiratory Tract Diseases; Respiratory Tract Infections; Rifampin; Trimethoprim; Tuberculosis, Pulmonary | 1983 |
1 trial(s) available for metronidazole and ethambutol
| Article | Year |
|---|---|
Inefficacy of ethambutol, ethambutol plus isoniazid, INH plus rifampicin, co-trimoxazole and metronidazole in the treatment of kala-azar.
Topics: Antiprotozoal Agents; Drug Therapy, Combination; Ethambutol; Female; Follow-Up Studies; Humans; Isoniazid; Leishmaniasis, Visceral; Male; Metronidazole; Random Allocation; Rifampin; Trimethoprim, Sulfamethoxazole Drug Combination | 1989 |
12 other study(ies) available for metronidazole and ethambutol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Design, synthesis, and in vitro antiprotozoal, antimycobacterial activities of N-{2-[(7-chloroquinolin-4-yl)amino]ethyl}ureas.
Topics: Anti-Bacterial Agents; Antiprotozoal Agents; Drug Design; Giardia lamblia; Humans; Leishmania mexicana; Mycobacterium tuberculosis; Quinolines; Structure-Activity Relationship; Urea | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
Topics: Adenosine Triphosphate; Animals; Antitubercular Agents; Male; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Mycobacterium Infections, Nontuberculous; Mycobacterium smegmatis; Mycobacterium tuberculosis; Proton-Translocating ATPases; Quinolines; Rats, Sprague-Dawley; Sulfonamides; Tuberculosis | 2015 |
Mycobacterium ulcerans infection (Buruli ulcer): first reported case in a traveler.
Topics: Adult; Africa; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Ciprofloxacin; Clarithromycin; Cloxacillin; Ethambutol; Humans; Leg Ulcer; Male; Metronidazole; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Penicillins; Rifampin; Skin Diseases, Bacterial; Skin Transplantation; Travel; Trimethoprim, Sulfamethoxazole Drug Combination; Virulence | 1999 |
[Mycobacterium ulcerans infection treated by Rifater, pyrazynamide, Myambutol, and surgery: a case report with a 6-year follow-up].
Topics: Anti-Bacterial Agents; Buruli Ulcer; Child; Chloramines; Combined Modality Therapy; Drug Combinations; Drug Therapy, Combination; Ethambutol; Female; Follow-Up Studies; Humans; Isoniazid; Mastectomy; Metronidazole; Mycobacterium ulcerans; Nitrofurantoin; Pleurisy; Prednisolone; Pyrazinamide; Recurrence; Rifampin; Skin Transplantation | 2008 |
Antituberculosis Treatment in a Patient with Celiac Disease.
Topics: Aged; Antitubercular Agents; Celiac Disease; Diarrhea; Diet, Gluten-Free; Drug Compounding; Drug Substitution; Drug Therapy, Combination; Ethambutol; Glutens; Hemoptysis; Humans; Isoniazid; Male; Metronidazole; Moxifloxacin; Pyrazinamide; Rifampin; Smoking; Tomography, X-Ray Computed; Tuberculosis, Pulmonary | 2018 |